Phibro Animal Health (NASDAQ:PAHC) PT Raised to $13.00 at Barclays

Phibro Animal Health (NASDAQ:PAHCGet Free Report) had its price target raised by stock analysts at Barclays from $10.00 to $13.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “underweight” rating on the stock. Barclays‘s target price would suggest a potential downside of 25.93% from the company’s previous close.

Separately, StockNews.com raised shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $14.75.

Read Our Latest Stock Report on Phibro Animal Health

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC opened at $17.55 on Friday. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.16 and a quick ratio of 1.60. Phibro Animal Health has a 1-year low of $9.40 and a 1-year high of $17.89. The company has a market capitalization of $710.78 million, a price-to-earnings ratio of 54.85, a PEG ratio of 6.48 and a beta of 0.63. The business has a 50-day moving average of $13.65 and a 200-day moving average of $12.12.

Phibro Animal Health (NASDAQ:PAHCGet Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.06. The company had revenue of $249.90 million during the quarter, compared to the consensus estimate of $242.91 million. Phibro Animal Health had a net margin of 1.32% and a return on equity of 17.11%. On average, equities analysts anticipate that Phibro Animal Health will post 1.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently modified their holdings of the stock. Barclays PLC increased its holdings in Phibro Animal Health by 59.8% in the third quarter. Barclays PLC now owns 35,638 shares of the company’s stock valued at $456,000 after buying an additional 13,332 shares during the last quarter. Trexquant Investment LP increased its holdings in shares of Phibro Animal Health by 143.6% in the 3rd quarter. Trexquant Investment LP now owns 35,872 shares of the company’s stock valued at $458,000 after acquiring an additional 21,147 shares during the last quarter. Brandes Investment Partners LP increased its holdings in shares of Phibro Animal Health by 38.5% in the 3rd quarter. Brandes Investment Partners LP now owns 1,873,300 shares of the company’s stock valued at $23,922,000 after acquiring an additional 520,697 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Phibro Animal Health by 358.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,357 shares of the company’s stock valued at $27,000 after acquiring an additional 1,843 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Phibro Animal Health by 20.9% during the third quarter. New York State Common Retirement Fund now owns 69,944 shares of the company’s stock worth $893,000 after purchasing an additional 12,110 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

See Also

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.